Work

Alzheimer's drug‐development pipeline: 2016

Year: 2016

Type: article

Abstract: BACKGROUND: Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. METHODS: We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. RESULTS: There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying treatments (DMTs). Most DMTs address amyloid-related targets (76%). There are 45 agents in phase II being assessed in 52 clinical trials. Phase II trials include 30 DMTs, with 26 small molecules and 4 immunotherapies. There are 24 agents in the first phase of AD drug development. DISCUSSION: Amyloid is the principal target of late-stage development programs. There are relatively few agents in clinical trials for AD suggesting a need to amplify the drug discovery ecosystem.

Source: Alzheimer s & Dementia Translational Research & Clinical Interventions

DOI: 10.1016/j.trci.2016.07.001

Authors: Jeffrey Cummings, Travis Morstorf, Garam Lee

Institutions: Cleveland Clinic, Lou Ruvo Brain Institute, Touro University Nevada

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,540